全球癌症治疗市场新型药物输送系统研究报告 - 2023 年至 2030 年产业分析、规模、份额、成长、趋势与预测

全球癌症治疗市场对新型药物输送系统的需求预计将从 2022 年的 144.8 亿美元增至 2030 年的近 853.2 亿美元，2023-2030 年研究期间CAGR为 24.82%。

癌症治疗中的新型药物输送系统旨在以相对于身体其他部位增加特定部位药物浓度的方式输送药物。新型药物输送系统 (NDDS) 透过减少给药频率提供更好的患者依从性。 NDDS对于癌症治疗具有显着的优势，包括提高溶解度和生物利用度、降低毒性、最大治疗效果、持续和受控的药物输送、提高稳定性以及更好的物理和生化降解安全性。

市场动态：

由于癌症治疗的巨大益处，全球新型药物传输系统在癌症治疗市场上可能会扩大。此外，新型药物输送系统市场主要受到癌症发生率上升的影响。此外，开发新型药物传输技术的研究活动增加，同时对正在进行的研究计画的资助也有所增加。此外，用于癌症诊断和治疗的医疗保健支出的增加可能会推动 NDDS 市场的成长。然而，高昂的治疗成本可能会限制市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球癌症治疗新型药物传输系统市场的各个细分市场进行了包容性评估。癌症治疗产业中新型药物输送系统的成长和趋势为这项研究提供了整体方法。

区域分析：

本节涵盖区域展望，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲癌症治疗市场中新型药物输送系统当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。癌症治疗市场新药物输送系统的主要参与者包括 Teva Pharmaceutical Industries Ltd.、Johnson & Johnson Services, Inc.、GALEN、Merrimack Pharmaceuticals Inc.、Shire、Samyang Biopharmaceuticals Corporation、Celgene Corporation、Spectrum Pharmaceuticals Inc.、BTG 。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：癌症治疗中的新型药物输送系统 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按产品分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：COVID-19 爆发的影响分析

第 6 章：癌症治疗市场中的全球新型药物输送系统分析：副产品

• 按产品概述
• 历史和预测数据
• 按产品分析
• 奈米颗粒（脂质体、聚合物、胶束、其他奈米颗粒）
• 栓塞颗粒（PVA颗粒、药物洗脱珠、液体栓塞、其他栓塞颗粒）

第 7 章：癌症治疗市场中的全球新型药物输送系统分析：按地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概述、历史和预测销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概述、历史和预测销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概述、历史和预测销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概述、历史和预测销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概述、历史和预测销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 8 章：癌症治疗公司新型药物输送系统的竞争格局

• 癌症治疗市场竞争中的新型药物传输系统
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 9 章：公司简介

• 顶级公司市占率分析
• 市场集中度
• Teva Pharmaceutical Industries Ltd.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Johnson & Johnson Services Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• GALEN
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Merrimack Pharmaceuticals Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Shire
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Samyang Biopharmaceuticals Corporation
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Celgene Corporation
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Spectrum Pharmaceuticals Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• BTG
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

The global demand for Novel Drug Delivery Systems in Cancer Therapy Market is presumed to reach the market size of nearly USD 85.32 BN by 2030 from USD 14.48 BN in 2022 with a CAGR of 24.82% under the study period 2023 - 2030.

Novel drug delivery systems in cancer therapy aim to deliver medication in a manner that increases its concentration at a specific site relative to other parts of the body. A novel drug delivery system (NDDS) offers better patient compliance via the diminished frequency of dose. NDDS have significant advantages for cancer treatment, including improved solubility and bioavailability, reduced toxicity, maximum therapeutic effect, sustained and controlled drug delivery, increased stability and better security against physical and biochemical degradation.

MARKET DYNAMICS:

The global novel drug delivery systems in the cancer therapy market are likely to expand due to substantial benefits for cancer treatment. Also, the novel drug delivery systems market is mainly influenced by a rise in the incidences of cancer. Moreover, rise in research activities for the development of technologies of novel drug delivery coupled with augmented funding for ongoing research projects. Furthermore, a rise in healthcare expenditure for the diagnosis and treatment of cancer is likely to propel the NDDS market growth. However, the high cost of therapy may limit the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of novel drug delivery systems in cancer therapy. The growth and trends of novel drug delivery systems in cancer therapy industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the novel drug delivery systems in cancer therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• Nanoparticles (Liposomes, Polymers, Micelles, Other Nanoparticles)
• Embolization Particles (Pva Particles, Drug-Eluting Beads, Liquid Emboli, Other Embolization Particles)

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Novel Drug Delivery Systems in Cancer Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the novel drug delivery systems in cancer therapy market include Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., GALEN, Merrimack Pharmaceuticals Inc., Shire, Samyang Biopharmaceuticals Corporation, Celgene Corporation, Spectrum Pharmaceuticals Inc., BTG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY MARKET ANALYSIS BY PRODUCT

• 6.1 Overview by Product
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Product
• 6.4 Nanoparticles (Liposomes, Polymers, Micelles, Other nanoparticles) Historic and Forecast Sales by Regions
• 6.5 Embolization particles (PVA Particles, Drug-eluting Beads, Liquid Emboli, Other Embolization Particles) Historic and Forecast Sales by Regions

7 . GLOBAL NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY COMPANIES

• 8.1. Novel Drug Delivery Systems In Cancer Therapy Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Teva Pharmaceutical Industries Ltd.
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Johnson & Johnson Services Inc.
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. GALEN
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. Merrimack Pharmaceuticals Inc.
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Shire
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Samyang Biopharmaceuticals Corporation
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Celgene Corporation
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Spectrum Pharmaceuticals Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. BTG
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Product (USD MN)
• Nanoparticles (Liposomes, Polymers, Micelles, Other nanoparticles) Market Sales by Geography (USD MN)
• Embolization particles (PVA Particles, Drug-eluting Beads, Liquid Emboli, Other Embolization Particles) Market Sales by Geography (USD MN)
• Global Novel Drug Delivery Systems In Cancer Therapy Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Novel Drug Delivery Systems In Cancer Therapy Report
• Market Research Process
• Market Research Methodology
• Global Novel Drug Delivery Systems In Cancer Therapy Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Product
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Product (USD MN)
• Nanoparticles (Liposomes, Polymers, Micelles, Other nanoparticles) Market Sales by Geography (USD MN)
• Embolization particles (PVA Particles, Drug-eluting Beads, Liquid Emboli, Other Embolization Particles) Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.